GI Videos

At the 2019 Great Debates & Updates in GI Malignancies meeting, Dr Berlin discussed the standard first-line therapies available for pancreatic cancer.

At the 2019 Great Debates & Updates in GI Malignancies meeting, Dr Berlin discussed using second-line PRRT in patients with pNETs.

At the 2019 Great Debates & Updates in GI Malignancies meeting, Dr Van Cutsem talked about the novel therapies and targets in metastatic CRC.

At the 2019 Great Debates & Updates in GI Malignancies meeting, Dr Ilson discussed factors to consider when treating patients with esophageal cancer.

Josep Tabernero, MD, PhD, summarizes the overall survival results from the TAGS study of trifluridine/tipiracil vs placebo in patients with metastatic gastric cancer refractory to standard therapies.

Ghassan K Abou-Alfa, MD, shares his thoughts on a presentation given by Andrew X Zhu, MD, at the 2018 ESMO World Congress on Gastrointestinal Cancer on REACH and REACH-2 clinical trial data for ramucirumab as treatment in hepatocellular...

Ghassan K Abou-Alfa, MD, medical oncologist at the Memorial Sloan Kettering Cancer Center (New York, NY), discusses the biggest challenges that remain for the treatment of hepatocellular carcinoma. 

Ghassan K Abou-Alfa, MD, medical oncologist at the Memorial Sloan Kettering Cancer Center (New York, NY), discusses a few of the newer agents available for the treatment of hepatocellular carcinoma, and how these agents have impacted practice.